Biomeme, Inc. Receives 2023 PACT Enterprise Award for Life Sciences & Healthcare Emerging

Written By: Max Perelman

As a company, we measure our progress in the diagnostics we develop and deliver and the impact we have on global health. 

But awards are nice, too.

So we were humbled and honored to receive the PACT Enterprise Award for Life Sciences & Healthcare Emerging, a recognition that celebrates technological innovation in technology, life sciences, and investment among a diverse group of individuals and organizations who solve some of the world’s most complex challenges.

Biomeme was recognized for its contributions to testing solutions for all communities, no matter their size or resources, softwares, and pathogen diagnostics. Since the conception of Biomeme, we have fought to produce state-of-the-art testing solutions and it’s been an amazing journey these last 10 years

“In a decade, we went from our first prototype PCR thermocycler using a travel hair dryer and an iPhone 4, to being one of the nation’s leading biotechnology companies offering streamlined solutions for molecular detection,” Max Perelman, CEO of Biomeme said. 

We look forward to the next journey, but in the meantime, we’d like to explain how we got here in the first place.

The Future of Biomeme and Global Health

As you can imagine, working with an iPhone 4 and a hair dryer wasn’t exactly what we had in mind when we launched Biomeme, but we were never deterred by any roadblocks. 

Our testing and technologies reflect this ideal. 

Biomeme’s contributions to biowarfare agent detection, used by U.S. Special Operations Forces, drew a lot of attention and perhaps brought us this incredible award, and though we are grateful for that, we are focusing on the future to remain a leader in diagnostic testing. This includes one of the most essential components of our diagnostic framework, Host Response, a revolutionary understanding and data-driven approach to some of the world’s biggest issues.

Host Response-based diagnostics analyze the distinct indicators exhibited by the body, referred to as the Host, during its battle against an infection. Our initial Host Response-based diagnostic equips medical professionals with the ability to determine whether an illness stems from a bacterial or viral infection. This valuable information empowers them to make more informed decisions when prescribing antibiotics, which helps the fight against antimicrobial resistance and supports One Health efforts.  

It’s a huge undertaking, but we are honored to implement solutions and can’t wait to see what’s next. 

Get the latest tips from Biomeme shipped right to your inbox

Our Progress

How We’ve Risen to Meet Global Health Challenges

When people think about global health, they tend to think about far-flung locales and communities of people different from their own. But the biggest challenges to global health like pandemic...

Our Progress

Meet the New Biomeme: Where Global Health Solutions Are Discovered

A lot can change in a decade. We started 10 years ago as a venture among friends and family, each of whom was deeply and personally committed to impacting global health, each in their own way. Since...

Our Progress

Biomeme, Inc. Receives 2023 PACT Enterprise Award for Life Sciences & Healthcare Emerging

As a company, we measure our progress in the diagnostics we develop and deliver and the impact we have on global health. But awards are nice, too. So we were humbled and honored to receive the PACT...